(GKOS) Glaukos Corporation ANSOFF Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(GKOS) Glaukos Corporation Complete Analysis Pack
Make Smarter Expansion Decisions with the Full Report
This Glaukos Corporation Ansoff Matrix Analysis maps the company’s growth options across market penetration, market development, product development, and diversification to support research, strategy, or investment decisions; the page includes a real preview/sample of the analysis so you can judge style and substance before buying—purchase the full version to download the complete ready-to-use report.
Market Penetration
iStent use in cataract surgery
Glaukos uses iStent, iStent inject, and iStent inject W during cataract surgery, a high-volume procedure performed in millions of cases each year. The devices target mild-to-moderate open-angle glaucoma, where combining MIGS with lens surgery is a practical first step. Deeper use in this routine setting is the clearest share-gain path, because adoption can scale inside an existing surgery flow.
iStent inject W account growth
iStent inject W is a two-stent micro-bypass device in Glaukos Corporation’s existing iStent family, so it fits the same glaucoma surgery workflow that surgeons already use. That makes account growth easier because the switch is inside the current learning curve, not a new procedure. In market-penetration terms, Glaukos is selling a next-step upgrade to the same surgeon base, which usually supports faster adoption than a brand-new platform.
The product also helps deepen use in current MIGS accounts, where surgeons can keep treating mild-to-moderate open-angle glaucoma with the familiar catheter-based process. Since it builds on the earlier iStent line, the main growth lever is more use per account, not just more accounts. That is a strong fit for penetration strategy because it raises share inside installed surgeon centers.
U.S. direct sales organization
Glaukos uses a U.S. direct sales organization to sell into ophthalmology accounts, which supports repeat use and faster reorders. Direct coverage also gives tighter control over ordering and account penetration, a good fit for its surgical glaucoma franchise. The model matters at scale, with Glaukos reporting roughly $375 million in 2024 net sales.
Distributor coverage in international markets
Glaukos Corporation uses distributors outside the United States to sell its existing eye-care products into current overseas accounts, which is a straight market-penetration play. In 2025, the company kept its focus on international reach through indirect channels rather than changing the product mix, so it can lift share with lower launch risk and limited new R&D spend. The model works best where local access and surgeon relationships already exist.
- Pushes current products abroad
- Targets existing overseas accounts
- Raises share without redesigning products
Glaucoma specialist wallet share
Glaukos is a glaucoma-first Company, so selling iStent inject W, iDose TR, and other glaucoma tools to the same ophthalmic specialists boosts wallet share in current markets. Company reported 2025 net sales of $450.7 million, up 24% year over year, showing the reach of this penetration play. The logic is simple: more products per specialist means more revenue from the same care network.
Glaukos Deepens Glaucoma Penetration as 2025 Sales Jump 24%
Glaukos Corporation’s market penetration is strongest in glaucoma, where iStent inject W and iDose TR expand use inside the same surgeon base and cataract workflow. In 2025, net sales reached $450.7 million, up 24% year over year, showing deeper use of existing accounts. U.S. direct sales and overseas distributors both support repeat orders and faster account share gains.
| Metric | 2025 |
|---|---|
| Net sales | $450.7 million |
| Growth | 24% YoY |
| Core penetration | Existing glaucoma accounts |
What is included in the product
Detailed Word Document
Analyzes Glaukos Corporation’s growth strategy through market penetration, market development, product development, and diversification.
Editable Excel File
Helps Glaukos quickly clarify growth priorities across products and markets.
Reference Sources
Provides a concise, traceable bibliography of primary sources validating Glaukos's market, product, and expansion assumptions for Ansoff Matrix decisions.
Market Development
iStent family outside the United States
Glaukos already sells the iStent family outside the United States, so adding more countries is a pure geography play. The company had about $373 million in 2024 net sales and a global eye-care footprint across 30+ countries, which supports faster launch reuse. The same core MIGS technology can move into new markets with local registrations, distributor links, and surgeon training.
Distributor-led country entry
Glaukos Corporation’s distributor-led model makes country entry low-friction because it can sell existing devices abroad without rebuilding the product line. This fits market development: the company can use local partners to handle regulatory, sales, and service work, while keeping capital needs lower than setting up direct teams in every market. It is a fast way to extend proven products into new national markets.
New cataract surgery centers abroad
Glaukos Corporation grows abroad by placing iStent devices during cataract surgery, so the product stays the same while the addressable market expands. The play is to win cataract surgeons and centers in new countries that still have not adopted the technology. With millions of cataract procedures done each year worldwide, even small adoption gains can add meaningful recurring procedure volume.
International glaucoma referral networks
Glaukos can push its current glaucoma portfolio into international referral networks and specialty eye centers, which is classic market development: same products, new geographies. That matters because glaucoma affects about 80 million people worldwide, and the count is expected to rise to 111.8 million by 2040, so access outside the United States still has room to expand.
For Glaukos Corporation, this path can lift reach without waiting for a new product cycle, especially in countries where specialist-led care routes patients to a few high-volume centers. The play is simple: use proven U.S. products, plug into cross-border referral chains, and grow procedure volume from existing assets.
- Existing products, new international centers
- Targets high-burden glaucoma markets
- Scales reach without new launches
Broader ophthalmology market access
Glaukos Corporation can extend its current commercial footprint by using both direct sales and distributors to reach new ophthalmology markets as reimbursement, tender rules, and channel access shift. This mixed model supports faster entry into adjacent geographies without rebuilding the whole sales force, which matters in a global ophthalmology market that keeps fragmenting by country and payer.
- Uses one sales model, two access paths
- Fits changing market access rules
- Extends current ophthalmology footprint
Glaukos Scales Globally with a Low-Capital, Geography-First Play
Glaukos Corporation’s market development is a geography-first play: it can take iStent and other glaucoma devices into more countries without changing the core product. With about $373 million in 2024 net sales and a presence in 30+ countries, it can use distributors, local registrations, and surgeon training to expand access faster and with less capital.
| Metric | Data | Use |
|---|---|---|
| Net sales | $373 million | Base for expansion |
| Countries | 30+ | Launch reuse |
| Glaucoma patients | 80 million | Demand pool |
Preview Before You Purchase
Glaukos Corporation Reference Sources
This is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality, and the preview below is taken directly from the full report you'll download after payment.
Product Development
iStent Infinite standalone system
iStent Infinite is a standalone, three-stent system for refractory glaucoma, so it adds a distinct option to Glaukos Corporation’s glaucoma surgery portfolio. The product extends the company beyond earlier micro-invasive devices and targets patients who need more pressure control after prior therapy. In Ansoff terms, it is product development: a new device for an existing eye-care market.
iDose TR targeted implant
iDose TR is Glaukos Corporation’s targeted injectable implant, built on its micro-scale device platform to deliver therapeutic drug levels inside the eye. It widens Glaukos Corporation’s product mix beyond stent-only solutions and supports product development in the Ansoff Matrix. The FDA approved iDose TR in 2023, giving Glaukos Corporation a new growth lane in the glaucoma market.
Micro-scale device platform
Glaukos Corporation’s micro-scale device platform is the core of its implantable therapy model, and it powers iDose TR, the first FDA-approved intraocular travoprost implant for glaucoma. The platform creates a repeatable path for new ophthalmic products, which matters in a market where Glaukos posted 2024 net sales of about $419 million. That base supports future product expansion with less reinvention.
Standalone refractory glaucoma
Glaukos Corporation’s iStent Infinite targets standalone refractory glaucoma, a tougher use case than placing a stent during cataract surgery. It uses 3 trabecular micro-bypass stents and expands Glaukos Corporation’s surgical options beyond the cataract-linked market, which was a much larger 2025 revenue base for the company.
- Standalone surgery, not cataract-linked
- Built for refractory glaucoma
- 3-stent design
- Broadens treatment mix
Therapeutic medication delivery
iDose TR shifts Glaukos Corporation from improving aqueous outflow to sustained medication delivery, a real new product path in glaucoma care. FDA-approved in 2023, the tiny intracameral implant is designed to release travoprost for about 3 years, making drug delivery a bigger share of the portfolio.
- New product direction
- Long-acting drug delivery
- 3-year travoprost release
Glaukos Expands Glaucoma Care with Two New Growth Drivers
Glaukos Corporation’s product development strategy adds new devices to the same glaucoma market, with iStent Infinite for standalone refractory glaucoma and iDose TR for sustained drug delivery. Both expand the company’s surgical and implantable mix beyond cataract-linked stents.
iDose TR won FDA approval in 2023 and is designed to release travoprost for about 3 years, while iStent Infinite uses 3 trabecular micro-bypass stents to treat harder cases. That gives Glaukos Corporation two clear product-extension paths in one core eye-care market.
| Product | Product development fact |
|---|---|
| iStent Infinite | 3-stent system for refractory glaucoma |
| iDose TR | FDA-approved in 2023; ~3-year travoprost release |
Diversification
Corneal disorder therapies
Glaukos Corporation’s corneal disorder therapies push it beyond glaucoma devices into a second ophthalmic disease area, so this is clear diversification. The company’s iDose TR won FDA approval in 2024 for open-angle glaucoma and ocular hypertension, while its corneal portfolio adds new products for diseases like corneal edema and keratoconus. That widens Glaukos’s addressable market and reduces reliance on one therapy class.
Retinal disease therapies
Glaukos Corporation’s move into retinal disease therapies widens its reach beyond the iStent franchise and into a separate eye-care segment. The company said retinal diseases are a focus area, which gives it a bigger addressable market and reduces reliance on glaucoma alone; Glaukos reported 2024 net sales of about $367 million. That shift is clear diversification in the Ansoff Matrix.
Ophthalmic pharmaceutical enterprise
Glaukos Corporation describes itself as an ophthalmic medical technology and pharmaceutical enterprise, so this is diversification beyond surgical devices into drug-based therapy. That move adds a second revenue path and exposure to the wider eye-care market, not just MIGS hardware. The strategy also raises the company’s addressable market by pairing devices with prescription treatments.
Device and drug hybrid model
iDose TR pairs a micro-scale device with drug delivery, so Glaukos Corporation is moving beyond a micro-bypass stent into therapeutic delivery systems. That widens diversification by blending a device and a drug platform in one product class. In 2024, Glaukos Corporation reported net sales of $373.5 million, showing room to scale new categories.
- Device-plus-drug platform
- Different from stent-only sales
- Supports broader diversification
Multi-indication ocular platform
Glaukos Corporation’s multi-indication ocular platform now spans glaucoma, corneal disorders, and retinal diseases, so it is the clearest diversification move in the Ansoff Matrix. The company is no longer tied to one eye-care niche, and that broader reach lowers dependence on a single disease area. This also opens more cross-selling and R&D reuse across ophthalmology.
- Glaucoma, cornea, retina
- Broader ophthalmic exposure
- Strongest diversification path
Glaukos Expands Beyond Glaucoma With a Broader Eye-Care Platform
Glaukos Corporation’s diversification is visible in its move from glaucoma devices into corneal and retinal therapies, so it is no longer tied to one eye-care niche. That broader portfolio expands the addressable market and lowers dependence on iStent alone. In 2024, Glaukos Corporation reported net sales of $373.5 million.
| Metric | Data |
|---|---|
| 2024 net sales | $373.5 million |
| Core moves | Glaucoma, cornea, retina |
| Strategy | Device plus drug platform |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.